The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SCOUT-1: Prospective non-interventional study in patients with BRCA/HRD-tested ovarian cancer (OC) eligible for first-line (1L) platinum-based chemotherapy (NOGGO ov54).
 
Pauline Wimberger
Honoraria - Amgen; AstraZeneca; Eisai; MSD Oncology; Novartis/Pfizer; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Amgen; AstraZeneca; MSD Oncology; Novartis; PharmaMar; Roche Pharma AG; Tesaro
Travel, Accommodations, Expenses - Roche Pharma AG
 
Klaus Pietzner
Stock and Other Ownership Interests - BioNTech
Honoraria - AstraZeneca; MSD; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Tesaro/GSK
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Roche
 
Ioana Braicu
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Roche (Inst)
 
Regina Glowik
Employment - AstraZeneca
 
Matthias Rose
Honoraria - Novo Nordisk
Consulting or Advisory Role - AstraZeneca
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro